oxepins and monepantel

The correct use of pharmacology-based information is critical to design successful strategies for the future of parasite control in livestock animals. Integrated pharmaco-parasitological research approaches have greatly contributed to optimize drug activity. In an attempt to manage drug resistance in helminths of ruminants, combinations of two or more anthelmintics are being used or promoted, based on the fact that individual worms may have a lower degree of resistance to a multiple component formulation, when each chemical has a different mode of action compared to that observed when a single compound is used. However, as emphasized in the current review, the occurrence of potential pharmacokinetic and/or pharmacodynamic interactions between drug components highlights the need for deeper and integrated research to identify the advantages or disadvantages associated with the use of combined drug preparations. This review article provides integrated pharmacokinetic/pharmacodynamic and clinical pharmacology information pertinent to preserve the traditional and modern active ingredients as practical tools for parasite control. Novel pharmacological data on derquantel and monepantel, as representatives of modern anthelmintics for use in livestock, is summarized here. The article also summarizes the pharmaco-parasitological knowledge considered critical to secure and/or extend the lifespan of the recently available novel molecules.

Topics: Aminoacetonitrile; Animals; Anthelmintics; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Helminths; Indoles; Oxepins; Pharmacology, Clinical; Ruminants; Time

Anthelmintic resistance by gastrointestinal nematodes of sheep continues to be an issue of global interest. While the recent introduction in some countries of one or two new anthelmintic classes (amino-acetonitrile derivatives [AAD] and spiroindoles [SI]) has been welcomed, it is important that there is no relaxation in parasite control and the management of drug resistance. Monepantel (an AAD) was the first new anthelmintic to be approved for use (New Zealand, 2009) and was followed a year later in the same country by a combination of derquantel (a SI) and abamectin. The present study determined the efficacy of the new anthelmintic products and abamectin against fourth-stage larvae of macrocyclic lactone-resistant Teladorsagia spp. in lambs. Efficacies were calculated by comparing post-mortem nematode burdens of treated animals with those of untreated control sheep, and were 98.5, 86.3 and 34.0% for monepantel, abamectin/derquantel and abamectin, respectively. The nematode burdens of monepantel- and abamectin/derquantel-treated sheep were significantly lower than those sheep treated with abamectin and the untreated controls. Similarly, the burden of the monepantel group was significantly lower than that of the abamectin/derquantel group. These findings provide an opportunity to reinforce the recommendation that farmers and animal health advisors need to know the resistance status of nematode populations on subject farms to ensure effective control programs are designed and implemented. Such control programs should include an appropriate choice of anthelmintic(s), monitoring parasite burdens for correct timing of treatments, and pasture management to reduce larval challenge balanced with the maintenance of drug-susceptible populations in refugia.

Topics: Aminoacetonitrile; Animals; Anthelmintics; Drug Combinations; Indoles; Ivermectin; Larva; Nematoda; Nematode Infections; Oxepins; Sheep; Sheep Diseases

Drug resistance in gastrointestinal nematodes is a severe problem for sheep farmers. With the recent introduction of monepantel (Zolvix®) and of derquantel plus abamectin (Startect®) in New Zealand, two new anthelmintic classes will be available to control gastrointestinal nematodes. While monepantel covers a broad spectrum of nematodes, the efficacy of derquantel is mid-spectrum and limited to a smaller number of species and stages. The combination of derquantel and abamectin allows to enlarge the spectrum and to cover most parasitic nematodes in sheep. However, the question remained open, if the efficacy of the new anthelmintics can be maintained in the presence of severe anthelmintic resistance. The present study investigated the efficacy against adult stages of a multi-resistant Haemonchus contortus isolate. While monepantel resulted in 100 % elimination, derquantel in combination with abamectin resulted in efficacies <95 % (faecal egg counts and worm counts).

Topics: Aminoacetonitrile; Animals; Anthelmintics; Disease Models, Animal; Feces; Haemonchiasis; Haemonchus; Indoles; Ivermectin; Oxepins; Parasite Egg Count; Sheep; Treatment Outcome

Early in 2015, sheep in a summer rainfall area of NSW, Australia, displayed signs of haemonchosis despite treatment with monepantel. A faecal egg count reduction test (FECRT) was performed on yearlings with natural field infections using various anthelmintics. Only a four-way combination drench achieved a reduction in faecal egg count (FEC) greater than 95%. The combination contained abamectin, albendazole, levamisole and closantel. Treatments with a derquantel/abamectin combination, monepantel and moxidectin reduced FECs by 93, 31, and 30% respectively. Sheep treated with abamectin displayed an increase in FEC of 22%. Larval differentiation counts conducted 10days post-treatment showed that 100% of survivors were Haemonchus sp. This result confirms for the first time monepantel resistant Haemonchus in sheep in NSW, and is amongst the first of the Australian cases in sheep not associated with goats. A second FECRT was performed using sheep from the moxidectin and abamectin treatment groups in the first FECRT. In this second FECRT, monepantel treatment reduced FECs by 51% and 29% in the sheep previously treated with moxidectin and abamectin respectively. This suggests monepantel, in combination with moxidectin, may give some control against severely abamectin resistant Haemonchus.

Topics: Albendazole; Aminoacetonitrile; Animals; Anthelmintics; Australia; Drug Therapy, Combination; Feces; Haemonchiasis; Haemonchus; Indoles; Ivermectin; Macrolides; Male; Oxepins; Parasite Egg Count; Random Allocation; Salicylanilides; Sheep; Sheep Diseases; Treatment Failure

Since 2009 two new classes of anthelmintics have been registered for use in sheep in New Zealand. This raises challenging questions about how such new actives should be used, not only to minimise the development of resistance to them, thereby ensuring their availability as effective treatments for as long as possible, but also to minimise the further development of resistance to the other anthelmintic classes. One strategy which appears to offer considerable potential for slowing the development of resistance is the use of combinations of different anthelmintic classes, although this approach remains contentious in some countries. The potential benefit of using anthelmintics in combination is particularly relevant to two recently released anthelmintic compounds because one, monepantel, is presently only available as a single active product while the other, derquantel, is only available in combination with abamectin. A simulation modelling approach was used to investigate the potential benefits of using anthelmintics in combination. The rate at which resistance develops to a new 'active' when used alone was compared to an equivalent compound used in combination with a second compound from an alternative class (in this case, abamectin), when various levels of resistance occur to the second active. In addition, the potential of a new active to reduce further development of resistance to the second compound in the combination was evaluated. Finally, the use of combinations as compared to sequential or rotational use patterns, in the presence of side resistance between two actives was investigated. The modelling simulations suggest a significant advantage to both compounds when they are used in combination, especially if both initially have high efficacy. The development of resistance to the new active was delayed, although to a lesser extent, even when the efficacy of the second active in the combination was only 50%. Under a 'low-refugia' management environment resistance to all actives developed more rapidly, and the advantage of using actives in combination was reduced. When used in conjunction with other resistance management strategies, a combination containing a new active prevented further development of resistance to the older class. Using actives in combination was superior to using them individually either sequentially or in rotation, even in the presence of side-resistance between the two anthelmintic classes.

Topics: Aminoacetonitrile; Animal Husbandry; Animals; Anthelmintics; Computer Simulation; Drug Resistance; Drug Therapy, Combination; Gene Frequency; Genotype; Indoles; Ivermectin; Nematoda; Nematode Infections; New Zealand; Oxepins; Sheep; Sheep Diseases; Sheep, Domestic; Time Factors